Healthcare and Medical Stock News: Comprehensive Care Corporation (OTCBB: CHCR) Names Colonel Ramon Martinez Senior Management Advisor To Maximize its Market Share with New Pharmacy Initiatives

TAMPA, Fla. - August 2, 2012 (Investorideas.com newswire) Comprehensive Care Corporation ("CompCare" or the "Company") (OTCBB: CHCR), which provides behavioral health, substance abuse and psychotropic pharmacy management services, has retained Ramon Martinez, a U.S. Air Force Lieutenant Colonel, retired, and leading figure in public management at state, national and international levels, as senior advisor to the Company's management. Colonel Martinez will spearhead the development and implementation of a Company mission, vision and strategy design, integrating the Company's behavioral health program with its innovative pharmacy cost containment program. The goal of this initiative is to maximize the Company's market share in both behavioral health and pharmacy management.

"An integral part of the Company's newly designed pharmacy program is the retaining of top-tiered senior advisors to assist the Company in this growth initiative," said Clark A. Marcus, Chairman and CEO. "Management believes that by attracting senior-level business executives to work with our senior management team as advisors, we enhance our ability to reach out to and attract the type of accounts who ultimately benefit the most from the Company's pharmacy cost-containment program."
"We are delighted to have Colonel Martinez join us as the first member of our team of senior advisors," continued Mr. Marcus. "Colonel Martinez's military and public sector background brings a wealth of experience to the Company, and we look forward to having him share with us his creative ideas and vision as to how we might even better enhance our pharmacy initiative. We will also look forward to working with Colonel Martinez in enlarging the scope of the market for our pharmacy initiative beyond that already contemplated by the Company."
Colonel Martinez served a twenty-year military career in the regular component of the US Air Force, climbing the ranks to become Combat Crew Commander, Test Director and Program Manager of Inter-Continental Ballistic Missiles; Assistant Professor of Philosophy at the US Air Force Academy; Deputy Secretary of the Inter-American Defense Board; US National Defense Fellow; Chief of Latin American Strategy of US Southern Command; and Interim Director of the US Southern Command Washington Field Office. He currently serves as senior consultant for XTek Solutions, a national and international consulting firm that uses advanced techniques to empower customers to sustain healthy growth.
Colonel Martinez earned a Master of Arts degree in philosophy from the University of California at Santa Barbara, a Master's degree in public administration from the University of Northern Colorado, and a Bachelor of Arts degree in philosophy and geography from California State University at Long Beach.
Colonel Martinez entered the private sector as Vice President at Genetics & IVF Institute in Fairfax, VA, later served as Assistant Director of Strategic Planning at the South Florida Workforce Board, adjunct professor of philosophy at Miami-Dade Community College, and as a consultant working on Homeland Security issues. He also served as president/CEO of Progreso Latino, Inc., the state of Rhode Island's flagship Latino empowerment agency and largest bilingual, multi-cultural community based organization.
Colonel Martinez is recipient of the Hispanic American Chamber of Commerce of Rhode Island Community Leader of 2009; National Association for the Advancement of Colored People (NAACP) Providence Branch Thurgood Marshall Award of 2008; 2008 Service Person of the Year Award of Sigma Nu Chapter Omega Psi Phi Fraternity, Inc. and The Providence Phoenix Newspaper Local Hero of 2008. He is vice chair and co-founder of the Board of Directors of the Rhode Island Mayoral Academies, and was lauded by the US Secretary of Education as a nationally unique paradigm for public education excellence with a mayor-led regional network of public charter schools serving underserved students. He served as a Trustee of Women and Infants Hospital and the Board of Directors of Clinica Esperanza/Hope Clinic, a free health clinic for the uninsured and underinsured of Rhode Island.
Colonel Martinez said, "Effective behavioral healthcare and pharmacy services are considered two crucial issues that currently impact the overall well-being of consumers and the healthcare economy as a whole. I became interested in CompCare because of its unique operating model designed to address these issues and mutually benefit health plans, self-insured companies and individuals. I am excited to leverage my skills to support CompCare in becoming a thriving, resilient company that delivers on the value promised to its customers. I am also excited to be working with a highly experienced management team who are committed to driving CompCare's growth and competitive market edge. My goal is to work with the management team to introduce a resonating mission, guiding principles, and corporate strategy that propel the Company to the next level."
About CompCare:
Established in 1969, CompCare provides behavioral health, substance abuse and psychotropic pharmacy management services for managed care companies throughout the United States. Headquartered in Tampa, Florida, CompCare focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches to behavioral health that address both the specific needs of clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.compcare.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond CompCare's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, the ability of CompCare to maximize its market share with new pharmacy initiatives, the ability of CompCare and its staff to execute its business plan, the ability of CompCare to offer and sell any of its products at a profit, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new business, the profitability, if any, of our capitated contracts or other products, increases or variations in cost of care, seasonality, CompCare's ability to obtain additional financing, increased outsourcing of behavioral health services, and additional risk factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at www.sec.gov. Any forward- looking statement in this release speaks only as of the date on which it is made. CompCare assumes no obligation to update or revise any forward-looking statements.

Published at www.investorideas.com newswire

Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com and its SMS partner Running Bull OTC have been compensated by HRDN for one month of news, email and sms: twenty five thousand
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biotech and Pharma Stock News: BUYINS.NET Issues Sunshine Biopharma SqueezeTrigger Report

NEWPORT BEACH, Calif. - August 2, 2012 (Investorideas.com Newswire, Biotechindustrystocks.com) BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Sunshine Biopharma (OTC: SBFM) after releasing the latest short sale data through July 31, 2012. The total aggregate number of shares shorted since January 2010 is approximately 3.97 million shares. Approximately 40.11% of daily trading volume is short selling. The SqueezeTrigger price for all SBFM shares shorted is $0.47. A short squeeze is expected to begin when SBFM closes above its $0.47 SqueezeTrigger Price.

Click here to view Report: http://www.buyins.com/ reports/sbfm8-1-12.pdf
Click here for SqueezeTrigger: http://www.buyins.com/ images/sbfmstr8-1-12.jpg
Click here for Friction Factor: http://www.buyins.com/ images/sbfmff8-1-12.jpg
Friction Factor calculates if a fair market is being made in the shares of SBFM. 41% of the previous 37 trading days have been positive or bullish-biased and 59% have been negative or bearish-biased.
Regulation SHO requires bona-fide market-making activities to include making purchases and sales in roughly comparable amounts. The SEC has stated that bona-fide market-making DOES NOT include activity that is related to speculative selling strategies or investment purposes of the broker-dealer and is disproportionate to the usual market making patterns or practices of the broker-dealer in that security. Likewise, where a market-maker posts continually at or near the best offer, but does not also post at or near the best bid, the market-maker's activities would not generally qualify as bona-fide market-making. Moreover, a market-maker that continually executes short sales away from its posted quotes would generally not be considered to be engaging in bona-fide market-making.
BUYINS.NET monitors SBFM market-makers daily for compliance with Fair Market-Making Requirements of Regulation SHO.
About BUYINS.NET
BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies and comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with "Fair Market-Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.
INVESTMENTS & TRADING
SqueezeTrigger -- 34 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.
GATS -- tracks and quantifies known trading strategies.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. SBFM has paid $1,116 per month to purchase data to be provided in six monthly reports. SBFM has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Contact:
BUYINS.NET
Thomas Ronk
800-715-9999
tom@buyins.net
http://www.buyins.net

Published at Investorideas.com newswire

Learn more about Sunshine Biopharma Inc. (OTCBB:SBFM): Profile
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biotech Stock Trading News Alert: Sunshine Biopharma (OTCBB: SBFM) Gains over 20%

New York, New York - August 1, 2012 (Investorideas.com Newswire, Biotechindustrystocks.com) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Sunshine Biopharma Inc. (OTCBB: SBFM). The stock is trading up at $0.4250, gaining $0.0750 or 21.43% on over 70,000 shares.
The Company's most recent news was July 20th when it reported it had engaged Beta Pharma Canada Inc. to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug.
Adva-27a is Sunshine Biopharma's lead anti-cancer compound which has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
Recent Q&A with Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc. (OTCBB: SBFM) at Investorideas.com
http://www.investorideas.com/CO/SBFM/news/2012/07021.asp

Recent CFA commentary:
http://www.investorideas.com/CO/SBFM/ news/2012/07301.asp
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Research biotech stocks at the Investor Ideas Biotech stocks Directory
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Healthcare Stock News; Comprehensive Care (OTCBB: CHCR) Research Report; Price Target of $0.40

New York, New York - August 1, 2012 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and healthcare stocks, releases research coverage and recent news for managed care stock, Comprehensive Care Corporation (OTCBB: CHCR). The Company provides behavioral health, substance abuse and psychotropic pharmacy management services for managed care companies throughout the U.S.

Research from SmallCaps.Us - Issued July 2012
http://smallcaps.us/reports/CR_CHCR_2012_Q2.pdf
'Based on 2012 revenue estimates of $72.5 million and earnings of $1.15 million, we reiterated our buy recommendation for Comprehensive Care Corporation with a price target of $0.40, which is more than double today’s stock price.”
Recent News
Healthcare Stocks: Comprehensive Care Corporation (OTC:CHCR) Retained by CHRISTUS Health to Provide Behavioral Health Management Services
TAMPA, Fla. - July 30, 2012 (Investorideas.com newswire) - Comprehensive Care Corporation (OTCBB: CHCR), which provides behavioral health, substance abuse and psychotropic pharmacy management services for managed care companies throughout the U.S., is pleased to announce that it has been retained by CHRISTUS Health Plan to provide managed behavioral health services to the Medicaid (STAR) and Children's Health Insurance Program (CHIP) populations served in the Nueces Service area, which is comprised of fourteen counties in the Coastal Bend region of Texas.
http://www.investorideas.com/CO/CHCR/news/2012/07301.asp
Profile page at Investorideas.com
http://www.investorideas.com/CO/CHCR/
About CompCare (OTCBB: CHCR) Established in 1969, CompCare provides behavioral health, substance abuse and employee assistance programs for governmental agencies, managed care companies and employer groups throughout the United States. Headquartered in Tampa, Florida, CompCare focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches to behavioral health that address both the specific needs of clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.compcare.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
All investment involves risk. The opinion of smallcaps.us is not the opinion or research of Investorideas.com Disclosure: Investorideas.com is compensated for publishing and distributing news for CHCR: four thousand for one month by third party IR firm
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - Investorideas.com
Contact Investorideas.com
800-665-0411

Biotech and Pharma Stock Alert; Aethlon Medical (OTCBB: AEMD) Reports Undetectable Hepatitis C Virus (HCV) Seven Days After Initiation of Hemopurifier® Therapy in Genotype-1 Patients

SAN DIEGO - July 31, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, reported today that the two most recent hepatitis c (HCV) infected patients to receive Hemopurifier® therapy in combination with peginterferon+ribavirin (PR) drug therapy achieved undetectable viral load at day-7, which represents a significant clinical milestone in HCV care. The Aethlon Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of HCV from the entire circulatory system to improve benefit, dose, duration and tolerability of drug therapies.

The Aethlon study is being conducted at the Medanta Medicity Institute (Medicity), a $360 million multi-specialty medical institute established to be a premier center for medical tourism in India. The objective of the Medicity study is to evaluate the capability of the Aethlon Hemopurifier® to accelerate HCV RNA depletion at the outset of standard of care PR therapy. Specifically, HCV-infected individuals are enrolled to receive up to three, six-hour Hemopurifier® treatments during the first three days of PR drug therapy.
"The intermittent administration of our Hemopurifier® during just the first days of interferon-based therapy is contributing to accelerate the pace and likelihood of viral load declining to undetectable levels," stated Aethlon Chairman and CEO, Jim Joyce. "We are now focused on expanding access to Hemopurifier® therapy and increasing dosing schedules to further optimize treatment outcomes."
The primary clinical endpoint of the Medicity protocol has been to increase the incidence of rapid virologic response (RVR), defined as undetectable HCV RNA at day 30 of therapy. RVR represents the clinical endpoint that best predicts treatment cure, otherwise known as sustained virologic response (SVR), defined as undetectable HCV RNA 24-weeks after the completion of PR drug therapy. As a point of reference, the landmark IDEAL Study of 3,070 HCV genotype-1 patients documented that only 10.35% (n=318/3070) of PR treated patients achieved a RVR. However, patients that achieved a RVR had SVR rates of 86.2% (n=274/318) versus SVR rates of 32.5% (n=897/2752) in non-RVR patients. While the incidence of undetectable HCV RNA at day-7 is not reported in the IDEAL study, the study did reveal that just 4.3% (n=131/3070) of patients achieved undetectable HCV RNA at day-14, which equated to a 91% (n=118/131) SVR rate.
In the Medicity study, Aethlon reported that Hemopurifier® therapy has been well tolerated and without device-related adverse events in ten treated patients. Of these ten patients, seven patients were infected with HCV genotype-1; two patients were infected with HCV genotype-3; and one patient was infected with HCV genotype-5. At present, undetectable HCV RNA is reported in eight of the 10 treated patients. Of the two patients with detectable HCV RNA, one discontinued PR therapy as a result of a diabetes related condition. HCV RNA is undetectable in all patients (n=4) that have been monitored for 48 weeks since receiving Hemopurifier® therapy. Among the 10 treated patients, Aethlon reported that six genotype-1 patients received the three treatment Hemopurifier® protocol, which resulted in four (67%) patients achieving a RVR. The IDEAL study predicts it would normally require approximately 40 PR treated patients to achieve 4 RVR outcomes. Both patients who achieved undetectable HCV RNA at day-7 also achieved a RVR. Beyond the high likelihood of a SVR, genotype-1 patients that achieve a RVR also have the opportunity to reduce the duration of PR drug therapy from 48 weeks to 24 weeks.
As a result of Hemopurifier® + PR therapy outcomes, Aethlon is seeking to establish clinical sites that will provide non-Indian citizens with access to Hemopurifier® therapy. A response from the Medicity internal review board (IRB) related to Aethlon's request to expand clinical programs at the Medicity is currently pending. Aethlon also disclosed that it is preparing to resubmit an investigational device exemption (IDE) to the FDA, which will incorporate the Medicity data, in an effort to gain approval to initiate HCV clinical programs in the United States.
It is estimated that approximately 4 million Americans and 170 million people worldwide are infected with HCV, which leads to chronic liver disease or cirrhosis, and is the leading cause of liver transplant in the U.S. To date, approximately 100 Hemopurifier® treatments have been administered in human studies. Previously, studies of the Hemopurifier® have been conducted at the Apollo, Fortis, and Sigma New Life hospitals in India. These studies demonstrated that Hemopurifier® therapy could safely reduce viral load in both HIV and HCV-infected dialysis patients without the administration of antiviral drug therapies. The Medicity study represents the first Hemopurifier® study in non-dialysis patients. In vitro studies have further validated the ability of the Hemopurifier® to capture a broad-spectrum of viral pathogens classified as bioterror or pandemic threats.

About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Biodefense Stock Trading Alert: PositiveID (OTCBB: PSID) Closes up over 13%

New York, NY - July 31, 2012 - (Investorideas.com Newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a trading alert for biodefense stock, PositiveIDCorporation (OTCBB: PSID), following recent news and developments for its M-BAND System for biothreat detection.

The stock closed trading on July 30th at $0.0260, gaining $0.0030, or 13.04% on over 1.9 Million shares. The Company recently reported it added Dr. Kimothy Smith as Chief Technology Advisor to the Company and its Microfluidic Systems ("MFS") subsidiary. The Company will utilize Dr. Smith's expertise in the areas of biosurveillance, biodefense, biosecurity, molecular genetics and diagnostics, as it prepares for the release of the final request for proposal from the Department of Homeland Security ("DHS") for BioWatch Generation 3, a $3.1 billion procurement for an early warning system designed to detect the intentional release of airborne biological agents. The Company believes its M-BAND system is one of the only technologies capable of addressing the requirements of BioWatch Generation 3.
Full news:
http://www.investorideas.com/CO/PSID/news/2012/07251.asp
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.www.PositiveIDCorp.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact
PSID:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com:
Contact: 800 665 0411

Healthcare Stocks: Comprehensive Care Corporation (OTC:CHCR) Retained by CHRISTUS Health to Provide Behavioral Health Management Services

TAMPA, Fla. - July 30, 2012 (Investorideas.com newswire) - Comprehensive Care Corporation ("CompCare" or the "Company") (OTCBB: CHCR), which provides behavioral health, substance abuse and psychotropic pharmacy management services for managed care companies throughout the U.S., is pleased to announce that it has been retained by CHRISTUS Health Plan (www.christushealthplan.org) to provide managed behavioral health services to the Medicaid (STAR) and Children's Health Insurance Program (CHIP) populations served in the Nueces Service area, which is comprised of fourteen counties in the Coastal Bend region of Texas.

This agreement is particularly important to CompCare as it is consistent with the Company's long-standing business strategy of being a prime provider of behavioral health services to Medicare, Medicaid and CHIP programs throughout the United States.
"New management has increased the number of states served by CompCare from eight states and Puerto Rico to 22 states, the District of Columbia and Puerto Rico," said Clark Marcus, CompCare Chairman and CEO. "This contract is an example of how we are continually growing CompCare for the ultimate benefit of our shareholders."
About CHRISTUS Spohn Health System
CHRISTUS Spohn Health System is the region's largest charity care provider and not-for-profit health care system consisting of six hospital campuses – CHRISTUS Spohn Hospital Corpus Christi (Shoreline, Memorial and South), CHRISTUS Spohn Hospital Alice, CHRISTUS Spohn Hospital Beeville and CHRISTUS Spohn Hospital Kleberg (Kingsville).
The health system is consistently ranked as a leading health system in the area and has received national recognition for several pioneering programs, including cardiac care, clinical excellence and oncology. For more than 100 years, CHRISTUS Spohn has been distinguished by its high caliber staff and affiliated physicians, its comprehensive and innovative services, and its long history of responding to the needs of the community it serves. For additional information, visit our website at www.christusspohn.org.
CHRISTUS Health Plan is a subsidiary of CHRISTUS Health delivering a broad range of health care services throughout Texas. CHRISTUS Health Plan combines the resources of physicians, multi-specialty groups, ambulatory care centers, ancillary providers and hospitals to offer members access to a comprehensive array of high quality health care.
About CompCare
Established in 1969, CompCare provides behavioral health, substance abuse and employee assistance programs for governmental agencies, managed care companies and employer groups throughout the United States . Headquartered in Tampa, Florida, CompCare focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches to behavioral health that address both the specific needs of clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.compcare.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release, including but not limited to our expected profitability in the second quarter of 2012, the continued implementation of our Pharmacy Management Program, the impact of the financial responsibility shift with one of our existing, at-risk pharmacy clients, our ability to increase margins and to obtain sustainable profitability, our ability to reduce overhead and implement further cost savings, our ability to further improve the Company's performance, the outcome of our business strategy, our ability to expand our pharmacy management program with higher profit margins, and our ability to reduce pharmacy expenses throughout the year are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the Company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new and existing business, our ability to expand and manage our provider network, the profitability, if any, of our recently acquired or previously existing capitated contracts, the costs incurred in seeking new contracts, the loss or termination of any existing contract, increases or variations in cost of care, seasonality, the Company's ability to obtain additional financing, and additional risk factors as discussed in the reports filed by the Company with the Securities and Exchange Commission, which is available on its website at www.sec.gov.
Investor Contacts:
Paul Knopick
E & E Communications
pknopick@eandecommunications.com
949.707.5365

Published at Investorideas.com Newswire

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
All investment involves risk. Disclosure: Investorideas.com is compensated for publishing and distributing news for CHCR: four thousand for one month by third party IR firm
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894